Skip to main content
Erschienen in: Annals of Surgical Oncology 2/2017

29.08.2016 | Hepatobiliary Tumors

Predictive Profile-Nomogram for Liver Resection for Breast Cancer Metastases: An Aggressive Approach with Promising Results

verfasst von: Aldrick Ruiz, MD, Dennis A. Wicherts, MD, PhD, Mylène Sebagh, MD, Sylvie Giacchetti, MD, Carlos Castro-Benitez, MD, Richard van Hillegersberg, MD, PhD, Bernard Paule, MD, Denis Castaing, MD, Jean-François Morère, MD, René Adam, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Breast cancer liver metastases (BCLM) are considered the most lethal compared with other sites of metastases in patients with breast cancer. This study aimed to evaluate the outcome after hepatectomy for BCLM within current multidisciplinary treatment and to develop a clinically useful nomogram to predict survival.

Methods

Between January 1985 and December 2012, 139 consecutive female patients underwent liver resection for BCLM at the authors’ institution. Clinicopathologic data were collected and analyzed for survival outcome with determination of prognostic factors. A nomogram to predict survival was developed based on a multivariate Cox model. The predictive performance of the model was assessed according to the C-statistic and calibration plots.

Results

After a median follow-up period of 55 months, the overall 3- and 5-year survival rates after hepatectomy were respectively 58 and 47 %. The median overall survival period was 56 months, and the median disease-free survival period after surgical resection was 33 months. A single hepatic metastasis, no triple negative tumors, no microscopic vascular invasion, and perioperative hormonal or targeted therapy were related to improved overall survival. The model achieved good discrimination and calibration, with a C-statistic of 0.80.

Conclusions

Liver resection for selected patients with breast cancer metastases can provide significant survival benefit. It should be part of a multidisciplinary treatment program in experienced liver surgery centers. The authors’ nomogram facilitates personalized assessment of prognosis for these patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
2.
Zurück zum Zitat Ge Q-D, Lv N, Kong Y-N, et al. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases. Asian Pacific J Cancer Prev. 2012;13:5081–6.CrossRef Ge Q-D, Lv N, Kong Y-N, et al. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases. Asian Pacific J Cancer Prev. 2012;13:5081–6.CrossRef
3.
Zurück zum Zitat Lobbezoo DJ, van Kampen RJ, Voogd AC, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013;141:507–14.CrossRefPubMed Lobbezoo DJ, van Kampen RJ, Voogd AC, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013;141:507–14.CrossRefPubMed
4.
Zurück zum Zitat O’Reilly SM, Richards MA, Rubens RD. Liver metastases from breast cancer: the relationship between clinical, biochemical, and pathological features and survival. Eur J Cancer Clin Oncol. 1990;26:574–7.CrossRef O’Reilly SM, Richards MA, Rubens RD. Liver metastases from breast cancer: the relationship between clinical, biochemical, and pathological features and survival. Eur J Cancer Clin Oncol. 1990;26:574–7.CrossRef
5.
Zurück zum Zitat Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004;22:3302–8.CrossRefPubMed Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004;22:3302–8.CrossRefPubMed
6.
Zurück zum Zitat Chia SK, Speers CH, D’Yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973–9.CrossRefPubMed Chia SK, Speers CH, D’Yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973–9.CrossRefPubMed
7.
Zurück zum Zitat Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2001;235:759–66.CrossRef Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2001;235:759–66.CrossRef
8.
Zurück zum Zitat Adam R, Aloia T, Krissat J, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 2006;244:897–907 (discussion 907–8). Adam R, Aloia T, Krissat J, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 2006;244:897–907 (discussion 907–8).
9.
Zurück zum Zitat Caralt M, Bilbao I, Cortes J, et al. Hepatic resection for liver metastases as part of the “oncosurgical” treatment of metastatic breast cancer. Ann Surg Oncol. 2008;15:2804–10.CrossRefPubMed Caralt M, Bilbao I, Cortes J, et al. Hepatic resection for liver metastases as part of the “oncosurgical” treatment of metastatic breast cancer. Ann Surg Oncol. 2008;15:2804–10.CrossRefPubMed
10.
Zurück zum Zitat Kollmar O, Moussavian MR, Richter S, et al. Surgery of liver metastasis in gynecological cancer: indication and results. Onkologie. 2008;31:375–9.CrossRefPubMed Kollmar O, Moussavian MR, Richter S, et al. Surgery of liver metastasis in gynecological cancer: indication and results. Onkologie. 2008;31:375–9.CrossRefPubMed
11.
Zurück zum Zitat Lubrano J, Roman H, Tarrab S, et al. Liver resection for breast cancer metastasis: does it improve survival? Surg Today. 2008;38:293–9.CrossRefPubMed Lubrano J, Roman H, Tarrab S, et al. Liver resection for breast cancer metastasis: does it improve survival? Surg Today. 2008;38:293–9.CrossRefPubMed
12.
Zurück zum Zitat Thelen A, Benckert C, Jonas S, et al. Liver resection for metastases from breast cancer. J Surg Oncol. 2008;97:25–9.CrossRefPubMed Thelen A, Benckert C, Jonas S, et al. Liver resection for metastases from breast cancer. J Surg Oncol. 2008;97:25–9.CrossRefPubMed
13.
Zurück zum Zitat Hoffmann K, Franz C, Hinz U, et al. Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann Surg Oncol. 2010;17:1546–54.CrossRefPubMed Hoffmann K, Franz C, Hinz U, et al. Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann Surg Oncol. 2010;17:1546–54.CrossRefPubMed
14.
Zurück zum Zitat Rubino A, Doci R, Foteuh JC, et al. Hepatic metastases from breast cancer. Updates Surg. 2010;62:143–8.CrossRefPubMed Rubino A, Doci R, Foteuh JC, et al. Hepatic metastases from breast cancer. Updates Surg. 2010;62:143–8.CrossRefPubMed
16.
Zurück zum Zitat Abbott DE, Brouquet A, Mittendorf EA, et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012;151:710–6.CrossRefPubMedPubMedCentral Abbott DE, Brouquet A, Mittendorf EA, et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012;151:710–6.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Duan XF, Dong NN, Zhang T, et al. Comparison of surgical outcomes in patients with colorectal liver metastases versus noncolorectal liver metastases: a Chinese experience. Hepatol Res. 2012;42:296–303.CrossRefPubMed Duan XF, Dong NN, Zhang T, et al. Comparison of surgical outcomes in patients with colorectal liver metastases versus noncolorectal liver metastases: a Chinese experience. Hepatol Res. 2012;42:296–303.CrossRefPubMed
18.
Zurück zum Zitat Groeschl RT, Nachmany I, Steel JL, et al. Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: a multi-institutional analysis. J Am Coll Surg. 2012;214:769–77.CrossRefPubMed Groeschl RT, Nachmany I, Steel JL, et al. Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: a multi-institutional analysis. J Am Coll Surg. 2012;214:769–77.CrossRefPubMed
19.
Zurück zum Zitat van Walsum GA, de Ridder JA, Verhoef C, et al. Resection of liver metastases in patients with breast cancer: survival and prognostic factors. Eur J Surg Oncol. 2012;38:910–7.CrossRefPubMed van Walsum GA, de Ridder JA, Verhoef C, et al. Resection of liver metastases in patients with breast cancer: survival and prognostic factors. Eur J Surg Oncol. 2012;38:910–7.CrossRefPubMed
20.
Zurück zum Zitat Dittmar Y, Altendorf-Hofmann A, Schule S, et al. Liver resection in selected patients with metastatic breast cancer: a single-centre analysis and review of literature. J Cancer Res Clin Oncol. 2013;139:1317–25.CrossRefPubMed Dittmar Y, Altendorf-Hofmann A, Schule S, et al. Liver resection in selected patients with metastatic breast cancer: a single-centre analysis and review of literature. J Cancer Res Clin Oncol. 2013;139:1317–25.CrossRefPubMed
21.
Zurück zum Zitat Kostov DV, Kobakov GL, Yankov DV. Prognostic factors related to surgical outcome of liver metastases of breast cancer. J Breast Cancer. 2013;16:184–92.CrossRefPubMedPubMedCentral Kostov DV, Kobakov GL, Yankov DV. Prognostic factors related to surgical outcome of liver metastases of breast cancer. J Breast Cancer. 2013;16:184–92.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Polistina F, Costantin G, Febbraro A, et al. Aggressive treatment for hepatic metastases from breast cancer: results from a single center. World J Surg. 2013;37:1322–32.CrossRefPubMed Polistina F, Costantin G, Febbraro A, et al. Aggressive treatment for hepatic metastases from breast cancer: results from a single center. World J Surg. 2013;37:1322–32.CrossRefPubMed
23.
Zurück zum Zitat Kim JY, Park JS, Lee SA, et al. Does liver resection provide long-term survival benefits for breast cancer patients with liver metastasis? A single hospital experience. Yonsei Med J. 2014;55:558–62.CrossRefPubMedPubMedCentral Kim JY, Park JS, Lee SA, et al. Does liver resection provide long-term survival benefits for breast cancer patients with liver metastasis? A single hospital experience. Yonsei Med J. 2014;55:558–62.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Weinrich M, Weiss C, Schuld J, et al. Liver resections of isolated liver metastasis in breast cancer: results and possible prognostic factors. HPB Surg. 2014;2014:893829.CrossRefPubMedPubMedCentral Weinrich M, Weiss C, Schuld J, et al. Liver resections of isolated liver metastasis in breast cancer: results and possible prognostic factors. HPB Surg. 2014;2014:893829.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Couinaud C. Variations of the right bile ducts: the futility of complete anatomical classifications. Chirurgie. 1993;1993; 119:354–6. Couinaud C. Variations of the right bile ducts: the futility of complete anatomical classifications. Chirurgie. 1993;1993; 119:354–6.
26.
Zurück zum Zitat Ruiz A, Castro-Benitez C, Sebagh M, et al. Repeat Hepatectomy for Breast Cancer Liver Metastases. Ann Surg Oncol. 2015;22:1057–66.CrossRef Ruiz A, Castro-Benitez C, Sebagh M, et al. Repeat Hepatectomy for Breast Cancer Liver Metastases. Ann Surg Oncol. 2015;22:1057–66.CrossRef
27.
Zurück zum Zitat Zlotnik A, Abraira V. A general-purpose nomogram generator for predictive logistic regression models. Stata J. 2015;15:537–46. Zlotnik A, Abraira V. A general-purpose nomogram generator for predictive logistic regression models. Stata J. 2015;15:537–46.
28.
Zurück zum Zitat Abuzallouf S, Motawy M, Thotathil Z. Baseline staging of newly diagnosed breast cancer: Kuwait cancer control center experience. Med Princ Pract. 2007;16:22–4.CrossRefPubMed Abuzallouf S, Motawy M, Thotathil Z. Baseline staging of newly diagnosed breast cancer: Kuwait cancer control center experience. Med Princ Pract. 2007;16:22–4.CrossRefPubMed
29.
Zurück zum Zitat Schuetz F, Diel IJ, Pueschel M, et al. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol. 2007;196:342 e1–9. Schuetz F, Diel IJ, Pueschel M, et al. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol. 2007;196:342 e1–9.
30.
Zurück zum Zitat Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271–7.CrossRefPubMed Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271–7.CrossRefPubMed
31.
Zurück zum Zitat Pogoda K, Niwinska A, Murawska M, et al. Analysis of pattern, time, and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013;30:388.CrossRefPubMedPubMedCentral Pogoda K, Niwinska A, Murawska M, et al. Analysis of pattern, time, and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013;30:388.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Berman AT, Thukral AD, Hwang WT, et al. Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. Clin Breast Cancer. 2013;13:88–94.CrossRefPubMed Berman AT, Thukral AD, Hwang WT, et al. Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. Clin Breast Cancer. 2013;13:88–94.CrossRefPubMed
33.
Zurück zum Zitat Follana P, Barriere J, Chamorey E, et al. Prognostic factors in 401 elderly women with metastatic breast cancer. Oncology. 2014;86:143–51.CrossRefPubMed Follana P, Barriere J, Chamorey E, et al. Prognostic factors in 401 elderly women with metastatic breast cancer. Oncology. 2014;86:143–51.CrossRefPubMed
Metadaten
Titel
Predictive Profile-Nomogram for Liver Resection for Breast Cancer Metastases: An Aggressive Approach with Promising Results
verfasst von
Aldrick Ruiz, MD
Dennis A. Wicherts, MD, PhD
Mylène Sebagh, MD
Sylvie Giacchetti, MD
Carlos Castro-Benitez, MD
Richard van Hillegersberg, MD, PhD
Bernard Paule, MD
Denis Castaing, MD
Jean-François Morère, MD
René Adam, MD, PhD
Publikationsdatum
29.08.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2017
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5522-7

Weitere Artikel der Ausgabe 2/2017

Annals of Surgical Oncology 2/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.